title: [Eighty cases of chronic respiratory failure treated with home noninvasive positive pressure ventilation].
abstract: We studied the clinical features and efficacy of home noninvasive positive pressure ventilation (NPPV) therapy in 80 patients to ascertain its indications and problems. The causes of chronic respiratory failure were restrictive thoracic diseases of post-tuberculosis sequelae (40 cases) and kyphoscoliosis (9 cases), COPD (8 cases), bronchiectasis (7 cases), and interstitial pneumonia (4 cases). One year survival rate of the patients with post-tuberculosis sequelae was 76% and most of the patients who started NPPV at their acute exacerbation died within several months. About half of the patients of COPD improved their quality of life (QOL) through NPPV. However, their survival rate 3 months later was only 69%. More than half of the patients with bronchiectasis felt that their QOL was improved by NPPV. Most of the patients with interstitial pneumonia died within 3 months indicating that NPPV is less useful for improving QOL of interstitial pneumonia PaCO2, after home NPPV, decreased significantly in the responder group (70.0 +/- 15.4 vs. 57.6 +/- 10.7[SD]Torr, p < 0.05), while PaCO2 in the non-responder group was unchanged (65.4 +/- 12.1 vs. 64.2 - 10.4 [SD] Torr). Body Mass Index (BMI) in the responder group tended to be higher than in the non-responder group. In conclusion, the restrictive thoracic diseases with post-tuberculosis sequelae and kyphoscoliosis are a good indication for NPPV and the therapy is also useful for patients with bronchiectasis who can dispose of their sputum by themselves. Home NPPV is suitable for patients whose PaCO2 decreases through NPPV and whose BMI is relatively high. QOL of interstitial pneumonia barely improves through NPPV, because interstitial pneumonia with hypercapnia is at the terminal stage.
authors.affiliation: Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center.
authors.forename: Nobuaki
authors.initials: N
authors.lastname: Kobayashi
authors.forename: Naoki
authors.initials: N
authors.lastname: Miyazawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Ogura
authors.forename: Yuji
authors.initials: Y
authors.lastname: Watanuki
authors.forename: Mari
authors.initials: M
authors.lastname: Nakamura
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Hashizume
authors.forename: Satoko
authors.initials: S
authors.lastname: Kozawa
authors.forename: Miho
authors.initials: M
authors.lastname: Hayashi
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Yamaguchi
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Nakada
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Takahashi
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ishigatsubo
mesh_terms: D000368:Aged; D002908:Chronic Disease; D005260:Female; D018575:Home Care Services, Hospital-Based; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011175:Positive-Pressure Respiration; D011788:Quality of Life; D012131:Respiratory Insufficiency / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000628:therapy